{"id":1910,"date":"2020-11-11T14:42:59","date_gmt":"2020-11-11T19:42:59","guid":{"rendered":"https:\/\/cqdm.org\/en\/news-and-events\/cqdm-portfolio-company-mesentech-secures-new-capital-to-bring-lead-product-to-clinical-phase\/"},"modified":"2024-09-25T16:27:16","modified_gmt":"2024-09-25T20:27:16","slug":"cqdm-portfolio-company-mesentech-secures-new-capital-to-bring-lead-product-to-clinical-phase","status":"publish","type":"post","link":"https:\/\/cqdm.org\/en\/news-and-events\/cqdm-portfolio-company-mesentech-secures-new-capital-to-bring-lead-product-to-clinical-phase\/","title":{"rendered":"CQDM portfolio company Mesentech secures new capital to bring lead product to clinical phase"},"content":{"rendered":"<strong>Montreal &#8211; November 11 2020 &#8211;<\/strong> CQDM congratulates Mesentech on securing additional investment to support the clinical development of their bone-targeting drug candidate MES-1007, a drug with the potential to reverse bone wastage in Duchenne Muscular Dystrophy and other skeletal fragility diseases in pediatrics.\n\n<u>Link to Mesentech&#8217;s Press Release: <a href=\"\/\/www.cureduchenne.org\/press-release\/cure-duchenne-ventures-announces-funding-of-mesentech-inc-within-a-funding-collaboration-with-the-charles-h-hood-foundation\/&quot;\" target=\"&quot;_blank&quot;\" rel=\"&quot;noopener noopener\">click here.<\/a><\/u>\n\n\u201cCQDM&#8217;s investment enabled Mesentech to generate the safety data that validated our technology\u2019s ability to mitigate side effects that precluded previous drug-development efforts in this drug class. This was key data that our new partners required to support a clinical program for DMD,\u201d said Jonathan Polak, Mesentech\u2019s CEO.\n\n\u201cCQDM is proud of the impact that our investment has already had and is excited by the progress that Mesentech has made in advancing MES-1007 towards the clinic\u201d, said Jesse Paterson, CQDM\u2019S Senior Director, Business Development. \u201cThe investment by patient foundations such as CureDuchenne and the Charles H.\u00a0Hood Foundation (CHF) speaks to the tremendous potential for MES-1007 as a bone targeted therapy,\u201d added Jesse Paterson.\n\n<strong>About CQDM:<\/strong>\n\nCQDM is a biopharma-based research consortium created in 2008 with the mission to fund the development of innovative technologies to accelerate the discovery and development of drugs and vaccines. Its business model is based on a collaborative approach bringing together world-leading pharmaceutical organizations, Canadian biotech companies as well as the Canadian and Quebec governments who share the costs of the research. CQDM uses this leverage to reduce the risks inherent to early-stage biopharmaceutical research. In doing so, CQDM bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned. CQDM receives contributions from Quebec\u2019s Ministry of Economy and Innovation (MEI), from large pharmaceutical companies, and from the Government of Canada under the Business-Led Networks of Centres of Excellence Program (BL-NCE). For more information:\u00a0<a href=\"https:\/\/cqdm.orgen\">https:\/\/cqdm.orgen<\/a>\n\n<strong>About Mesentech:<\/strong>\n\nMesentech is a Vancouver-based biotechnology company dedicated to developing platform technologies to treat diseases and conditions of bones. Dr. Robert Young, founder of Mesentech, spearheaded the discovery of life-changing therapeutics such as Singulair\u00ae and Arcoxia\u00ae while leading medicinal chemistry at the Merck Frosst Centre for Therapeutic Research in Montreal.\n\n-30-\n\n<strong>Source :<\/strong>\n<strong>CQDM<\/strong>\nJesse Paterson\nSenior Director, Business Development\n+1 (514) 850-7088\n<a href=\"mailto:jpaterson@cqdm.org\">jpaterson@cqdm.org<\/a>\n<a href=\"https:\/\/cqdm.org\">www.cqdm.org<\/a>","protected":false},"excerpt":{"rendered":"<p>Montreal &#8211; November 11 2020 &#8211; CQDM congratulates Mesentech on securing additional investment to support the clinical development of their bone-targeting drug candidate MES-1007, a drug with the potential to reverse bone wastage in Duchenne Muscular Dystrophy and other skeletal fragility diseases in pediatrics. Link to Mesentech&#8217;s Press Release: click here. \u201cCQDM&#8217;s investment enabled Mesentech&hellip;<\/p>\n","protected":false},"author":2,"featured_media":1138,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1910","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-our-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/1910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/comments?post=1910"}],"version-history":[{"count":1,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/1910\/revisions"}],"predecessor-version":[{"id":4842,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/1910\/revisions\/4842"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/1138"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=1910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/categories?post=1910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/tags?post=1910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}